AXIM® Biotechnologies Commences Commercial Manufacturing of FDA-Cleared Proprietary Ocular…
<!-- Name:DistributionId Value:8805377 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->
<!-- Name:IcbCode Value:4573 -->…
Browsing Tag
AXIM BIOTECHNOLOGIES
AXIM® Biotechnologies Files Provisional Patent on Novel Methodology for Use in Optical Diagnostic…
<!-- Name:DistributionId Value:8787616 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->
<!-- Name:IcbCode Value:4573 -->…
AXIM® Biotechnologies Develops Novel Dual IgE/MMP-9 Rapid Ophthalmological Diagnostic Test; Files…
SAN DIEGO, Dec. 13, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare diagnostic solutions development company, announced today that it has filed a…
AXIM Biotechnologies Commercial Partner Verséa Ophthalmics Highlights Benefits of AXIM’s Eye…
SAN DIEGO, Dec. 06, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare diagnostic solutions development company, today announced that its ophthalmic…
AXIM® Biotechnologies Receives Initial Order for Diagnostic Solutions as Exclusive Partner Verséa…
SAN DIEGO, Oct. 04, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare diagnostic solutions development company, announced today that it has received…
AXIM® Biotechnologies Point-of-Care Diagnostic Test Platform Sales Commence With Verséa Ophthalmics’…
SAN DIEGO, Sept. 29, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting ocular surface diseases, announced today that it…
AXIM® Biotechnologies Signs Exclusive Global Commercialization Agreement With Verséa™ Ophthalmics…
SAN DIEGO, Sept. 19, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech” or “AXIM”), an international healthcare solutions company targeting ocular surface diseases, announced today that it has signed an…
AXIM Biotechnologies Publishes Study Highlighting Neutralizing Antibody Levels of Poor Vaccine…
SAN DIEGO, July 12, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company, announced today their publication in collaboration with…
AXIM Biotechnologies Applauds FDA’s Recent COVID-19 Test Policies to Support Rapid…
SAN DIEGO, Nov. 18, 2021 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” or “the Company”), an international healthcare solutions company targeting oncological, COVID-19 and Dry Eye Disease (DED)…
AXIM Biotechnologies Partners with Arizona State University to Determine Antibody Levels Against…
SAN DIEGO, Nov. 16, 2021 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting COVID-19 diagnostics and oncological research,…